DMF Medical’s project fast-tracked the regulatory approval and manufacturing of memsorb™, a medical-membrane based CO2 filtration technology, to support the repurposing of anesthesia machines to act as closed-loop ICU ventilators to address critical shortages during the Covid-19 pandemic. The use of medical membranes eliminates the mandatory replacement and monitoring of chemical absorption components and allows for continuous use while eliminating performance issues related to chemical absorbers. Post-Covid, memsorb™ will support hospitals in their greening and sustainability initiatives by reducing their environmental impact. memsorb™ provides numerous advantages over current technologies including longer life, elimination of waste, reduced greenhouse gas emissions, elimination of chemical byproducts, and increased machine reliability.
